Introduction：Basic information about Pamidronate disodium salt CAS 57248-88-1, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Pamidronate disodium salt Basic information
| Product Name: | Pamidronate disodium salt |
| Synonyms: | 3-Amino-1-hydroxy-1-phosphonopropyl phosphonic acid disodium salt;Pamidronate Disodium, GCP-23339A, Aminomux, Aredia;Pamidronic Acid, Sodium Salt, Hydrate;Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt;(3-amino-1-hydroxypropylidene)bis-phosphonic acid disodium salt;disodium dihydrogen (3-amino-1-hydroxypropylidene)bisphosphonate;PAMIDRONATE DISODIUM SALT HYDRATE;(3-AMINO-1-HYDROXYPROPYLIDINE)BIS-PHOSPHONIC ACID |
| CAS: | 57248-88-1 |
| MF: | C3H12NNaO7P2 |
| MW: | 259.07 |
| EINECS: | 260-647-1 |
| Product Categories: | Bone Resorption Inhibitor;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Phosphorylating and Phosphitylating Agents;API's;Pharmaceutical material and intermeidates;Antibiotics;API;Aredia |
| Mol File: | 57248-88-1.mol |
|
Pamidronate disodium salt Chemical Properties
| Melting point | 300 °C |
| storage temp. | 2-8°C |
| solubility | H2O: 28 mg/mL |
| form | solid |
| color | white |
| Water Solubility | H2O: 28mg/mL |
| Merck | 14,7003 |
| Stability: | Hygroscopic |
| InChI | 1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2 |
| InChIKey | TVQNUQCYOOJTMK-UHFFFAOYSA-L |
| SMILES | O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O |
| CAS DataBase Reference | 57248-88-1(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xn |
| Risk Statements | 22-48-41-37/38-20/21/22 |
| Safety Statements | 22-26-36/37/39-45 |
| RIDADR | 3077 |
| WGK Germany | 3 |
| RTECS | SZ6525000 |
| HazardClass | IRRITANT |
| HS Code | 29319090 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
Pamidronate disodium salt Usage And Synthesis
| Description | Disodium pamidronate is a calcium metabolism regulator useful in the treatment ofhypercalcemia associated with malignancy. It presumably reduces the bone resorption ofcalcium by inhibiting the formation and attachment of osteoclasts. Other potential usesinclude osteoporosis and calcitonin-resistant Paget’s disease. |
| Chemical Properties | White Crystals |
| Originator | Henkel (United Kingdom) |
| Uses | Pamidronate disodium is a nitrogen containing bisphosphonate, used to prevent osteoporosis. It is used to prevent bone loss, and treat osteoporosis. |
| Uses | A farnesyl diphosphate synthase inhibitor |
| Uses | A bisphosphonate antiresorptive agent; bone resorption inhibitor. |
| Manufacturing Process | For a batch size of 5 L, 587.5 g (3.2 moles) of mannitol is dissolved in 3.5 L of water. Pamidronic acid (31.6 g, 0.133 moles) is mixed with a 1.0 L aliquot of the mannitol solution to form a slurry. The slurry is then transferred into the remainder of the mannitol solution, and stirred for at least 15 min. Aqueous 1 N sodium hydroxide (270 ml) is then added and the mixture is stirred until a clear, colorless solution results. The pH is then adjusted to 6.50.1 using either 1 M aqueous phosphoric acid or 1 N aqueous sodium hydroxide, as needed. The solution is then filtered through a 0.22 micron filter, and filled at 20°C into vials at 4.0 ml (4.172 g)/vial, under sterile conditions. The aqueous solution is frozen at -37°C and lyophilized (20 mbar, 20°-40°C) to yield 1,250 vials, each containing 30 mg of amorphous disodium pamidronate. The vials are sealed under positive nitrogen pressure. The disodium pamidronate is amorphous (noncrystalline) by X-ray diffraction and contains 0.7 wt-% water. |
| Brand name | Aredia (Novartis). |
| Therapeutic Function | Bone resorption suppressant |
| Biochem/physiol Actions | Pamidronate disodium?has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth. |
| Veterinary Drugs and Treatments | Pamidronate may be useful in treating hypercalcemia associatedwith vitamin D-related toxicoses or hypercalcemia of malignancy.There is ongoing research on the use of this drug to determine ifit has clinical usefulness in directly treating “micro-metastases” inosteosarcomas. |
Pamidronate disodium salt Preparation Products And Raw materials
| Raw materials | Sodium hydroxide-->Pamidronic acid-->Mannitol |
